^
    Apply
    A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors (TranStar102) (NCT04495296)
    Phase 1/2
    Suzhou Transcenta Therapeutics Co., Ltd.
    Recruiting
    Last update posted :
    10/21/2024
    Initiation :
    08/13/2020
    Primary completion :
    02/25/2025
    Completion :
    05/01/2025
    HER-2 • CLDN18
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)
    Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma (NCT06093425)
    Phase 3
    Suzhou Transcenta Therapeutics Co., Ltd.
    Not yet recruiting
    Last update posted :
    10/20/2023
    Initiation :
    10/31/2023
    Primary completion :
    10/01/2025
    Completion :
    01/31/2026
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer (NCT05190575)
    Phase 2
    Shanghai Zhongshan Hospital
    Completed
    Last update posted :
    07/27/2023
    Initiation :
    01/14/2022
    Primary completion :
    05/06/2023
    Completion :
    05/06/2023
    CLDN18
    |
    CLDN18.2 expression
    |
    osemitamab (TST001)